Atezolizumab-induced scleroderma: a rare complication
| Autor: | Varun Chalasani, Adam Dore, Jeffrey Uchin, Christon Grant |
|---|---|
| Rok vydání: | 2023 |
| Předmět: |
medicine.medical_specialty
Chemotherapy Lung Neoplasms integumentary system medicine.diagnostic_test business.industry medicine.medical_treatment Autoantibody General Medicine medicine.disease Antibodies Monoclonal Humanized Dermatology Connective tissue disease Rheumatology Scleroderma Scleroderma Localized Atezolizumab Internal medicine Carcinoma Non-Small-Cell Lung Skin biopsy Medicine Humans Female business Complication |
| Zdroj: | BMJ case reports. 14(11) |
| ISSN: | 1757-790X |
| Popis: | Few cases of programmed death-ligand 1 inhibitor-induced scleroderma have been reported and their clinical features remain unpublished. Optimal management is, therefore, unknown and an autoantibody association has yet to be identified. We present the case of a female in her 60s who developed skin thickening after starting atezolizumab for metastatic non-small cell lung cancer. Skin biopsy 7 months after symptom onset showed histological changes consistent with scleroderma. Anti-PM/SCL-75 antibody was positive. Atezolizumab was discontinued and treatment was started with mycophenolate mofetil. After 5 months, she experienced mild improvement in skin thickening. Earlier identification of this complication may limit morbidity in this disease process, which otherwise has limited treatment options. In suspected cases, obtaining scleroderma-associated autoantibodies may help with earlier diagnosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|